Clinical trial
An Open-label Extension Study Evaluating the Long-term Safety and Efficacy of Oral Inhalation of GB002 for the Treatment of WHO Group 1 Pulmonary Arterial Hypertension (PAH)
NCT04816604 is registered in ClinicalTrials.gov with Gossamer Bio USA, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-label Extension Study Evaluating the Long-term Safety and Efficacy of Oral Inhalation of GB002 for the Treatment of WHO Group 1 Pulmonary Arterial Hypertension (PAH)
- Lead sponsor
- Gossamer Bio USA, Inc.
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- April 5, 2021
- Completion date
- September 9, 2026
- Enrollment
- 74 (actual)
- Sites
- 28
Conditions
As the registry lists them; a condition with its own page is linked.